Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ventricular Tachycardia Ablation vs. Enhanced Drug Therapy in Structural Heart Disease.

Next Previous
Trial Profile

Ventricular Tachycardia Ablation vs. Enhanced Drug Therapy in Structural Heart Disease.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amiodarone (Primary) ; Mexiletine (Primary)
  • Indications Ventricular tachycardia
  • Focus Therapeutic Use
  • Acronyms VANISH

Most Recent Events

  • 12 Jul 2022 Status changed to completed , according to Results published in the Europace
  • 12 Jul 2022 Results published in the Europace
  • 21 Jun 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top